Literature DB >> 21220215

Change in IgG and evolution of lung function in children with cystic fibrosis.

M Proesmans1, C Els, F Vermeulen, K De Boeck.   

Abstract

Reports from the seventies and eighties have shown that cystic fibrosis (CF) patients with severe lung disease have high levels of IgG and that this is associated with worse prognosis. We decided to explore IgG level as a possible outcome parameter for lung disease severity in a cohort of pediatric CF patients treated according to current standards of care. Seventy three CF children older than 5 years (and max 15 years old at the initial evaluation) attending the same CF center were followed during a period of 4 years. Data collection included spirometry, height, weight, sputum cultures and total IgG. Median age at the start was 10 years. IgG z scores<2 SD were seen in 2.7% of patients in 2004 and 2008. Twelve patients (16%) had an IgG>2 SD in 2004 and this number increased to 18 (25%) in 2008. IgG z-scores were inversely correlated with FEV(1)% predicted (r=-0.323 in 2004; p<.001). In longitudinal evaluation, changes in IgG z-score correlate inversely with changes in FEV(1)% predicted (r=-0.498; p<.001). We can conclude that even for CF patients treated according to current standards IgG z-score increases with age and is correlated with a decline in FEV(1).
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220215     DOI: 10.1016/j.jcf.2010.12.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  12 in total

Review 1.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

2.  Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.

Authors:  Scott D Sagel; Brandie D Wagner; Assem Ziady; Tom Kelley; John P Clancy; Monica Narvaez-Rivas; Joseph Pilewski; Elizabeth Joseloff; Wei Sha; Leila Zelnick; Kenneth D R Setchell; Sonya L Heltshe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2019-12-20       Impact factor: 5.482

3.  Vitamin D treatment modulates immune activation in cystic fibrosis.

Authors:  T Pincikova; D Paquin-Proulx; J K Sandberg; M Flodström-Tullberg; L Hjelte
Journal:  Clin Exp Immunol       Date:  2017-05-24       Impact factor: 4.330

Review 4.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

Review 5.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

6.  Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.

Authors:  Jordana E Hoppe; Brandie D Wagner; J Kirk Harris; Steven M Rowe; Sonya L Heltshe; Emily M DeBoer; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2022-04-16       Impact factor: 5.527

Review 7.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

8.  Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Authors:  Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

9.  Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial.

Authors:  Ruth E Grossmann; Susu M Zughaier; Meena Kumari; Shabnam Seydafkan; Robert H Lyles; Shuling Liu; Viranuj Sueblinvong; Michael S Schechter; Arlene A Stecenko; Thomas R Ziegler; Vin Tangpricha
Journal:  Dermatoendocrinol       Date:  2012-04-01

10.  Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study.

Authors:  Mindy S Lo; David Zurakowski; Mary Beth F Son; Robert P Sundel
Journal:  Pediatr Rheumatol Online J       Date:  2013-11-01       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.